Literature DB >> 1335763

Establishment of a human T-cell line constitutively producing several eosinophil chemotactic lymphokines and their functional heterogeneity on eosinophils.

M Hirashima1, M Ueno, S Higuchi, T Matsumoto, K M Sakata, R Matsumoto, M Adachi.   

Abstract

We established a T-cell line, STO-2, by human T-cell lymphoma-leukemia virus-induced transformation of normal human T cells. Partial purification with isoelectric electrophoresis revealed that STO-2 liberated several eosinophil chemotactic factors (ECF) for eosinophils from healthy individuals with different isoelectric point of PI5, PI6, PI7, PI8, and PI9. Molecular weight of all the ECF was about 30,000 to 45,000. None of the ECF except ECF-PI5 was suppressed when they were incubated with monoclonal antibodies against IL-3, IL-5, and GM-CSF together, suggesting that ECF activity of ECF-PI5 is mainly comprised of IL-3, IL-5, and GM-CSF. ECF-PI5, PI6, and PI7 also exhibited enhancing activity on ex vivo eosinophil survival whereas ECF-PI8 and PI9 failed. Expression of Fc epsilon receptor II on eosinophils was potentiated by ECF-PI6 and ECF-PI7. In contrast, expression of Fc gamma receptor III was potentiated by ECF-PI7, ECF-PI8, and ECF-PI9. ECF-PI6 could also change an eosinophilic cell line, EOL-1, to eosinophilic granule-positive cells, whereas the rest of ECF failed. The above results suggested that eosinophils attracted by an ECF exhibit their biological functions, which differ from those of eosinophils attracted by other ECF. In further experiments, the chemotactic response of eosinophils from patients with eosinophilia was compared to that of eosinophils from healthy individuals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335763

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  3 in total

1.  Serum and synovial fluid levels of interleukin-5 in a patient with eosinophilic fasciitis.

Authors:  K Nishiya; N Tanimoto; K Hashimoto; M Hashizume; A Tominaga
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

Review 2.  Galectin-9 in physiological and pathological conditions.

Authors:  Mitsuomi Hirashima; Yumiko Kashio; Nozomu Nishi; Akira Yamauchi; Tada-atsu Imaizumi; Toshiro Kageshita; Naoki Saita; Takanori Nakamura
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 3.  Cancer Therapy Due to Apoptosis: Galectin-9.

Authors:  Koji Fujita; Hisakazu Iwama; Kyoko Oura; Tomoko Tadokoro; Eri Samukawa; Teppei Sakamoto; Takako Nomura; Joji Tani; Hirohito Yoneyama; Asahiro Morishita; Takashi Himoto; Mitsuomi Hirashima; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2017-01-01       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.